Strides Pharma Science is currently trading at Rs. 370.20, up by 5.95 points or 1.63% from its previous closing of Rs. 364.25 on the BSE.
The scrip opened at Rs. 369.00 and has touched a high and low of Rs. 373.25 and Rs. 364.05 respectively. So far 4790 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 466.60 on 18-Jan-2022 and a 52 week low of Rs. 263.45 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 392.20 and Rs. 359.05 respectively. The current market cap of the company is Rs. 3289.28 crore.
The promoters holding in the company stood at 31.07%, while Institutions and Non-Institutions held 36.90% and 32.03% respectively.
Strides Pharma Science’s step-down subsidiary---Strides Pharma Global has received AUD 94 million as the deferred consideration for the sale of the company’s Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet.
Strides, in 2019, exited its investments in Australia for AUD 394 million. The company received AUD 300 million immediately on the transaction's closing, and the same was used towards significant deleveraging of the balance sheet through repayment of debt. The balance of AUD 94 million was a deferred consideration backed by a secured interest-bearing instrument. Strides continues to be a preferred supplier to Arrotex, which is the largest generic company in Australia.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: